UK's Ashtead proposes move to U.S. listing; warns on profit-May 2024-www.financetom.com

UK's Ashtead proposes move to U.S. listing; warns on profit

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

UK's Ashtead proposes move to U.S. listing; warns on profit

Dec 9, 2024 11:33 PM

Dec 10 (Reuters) - UK equipment rental firm Ashtead

would shift its primary listing to the United States,

its biggest market, from London, and said on Tuesday it expects

annual profit to come in below its previous expectations.

Previous page： Walgreens settles New York charges it inflated prices of infant formula Next page： Atlassian Insider Sold Shares Worth $1,717,897, According to a Recent SEC Filing

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Walgreens settles New York charges it inflated prices of infant formula

Mar 11, 2024

NEW YORK (Reuters) - Walgreens has settled charges by New York Attorney General Letitia James that the pharmacy chain grossly inflated prices on at least 20 infant formula products in 2022 after a recall by Abbott Labs led to a nationwide shortage. Walgreens did not admit or deny wrongdoing in entering an assurance of discontinuance dated March 7 and made...

Atlassian Insider Sold Shares Worth $1,717,897, According to a Recent SEC Filing

Mar 11, 2024

05:26 PM EDT, 03/11/2024 (MT Newswires) -- Michael Cannon-Brookes, 10% Owner, Director, Co-CEO, Co-Founder, on March 08, 2024, sold 8,241 shares in Atlassian ( TEAM ) for $1,717,897. Following the Form 4 filing with the SEC, Cannon-Brookes has control over a total of 115,374 shares of the company, with 115,374 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1650372/000156218024002541/xslF345X03/primarydocument.xml Price: 215.82, Change: +0.19, Percent...

Acadia to stop trials of antipsychotic drug after it fails schizophrenia study

Mar 11, 2024

March 11 (Reuters) - Acadia Pharmaceuticals ( ACAD ) said on Monday it does not plan to conduct further clinical trials of its antipsychotic drug, pimavanserin, after it failed to improve negative symptoms of schizophrenia in a late-stage study. Shares of the California-based company fell 16% in extended trading. The decision comes after two failed attempts to secure regulatory approval...

BRIEF-Assure Holdings Enters Into Agreement To Sell Certain Of Its Assets To MPOWERHealth

Mar 11, 2024

March 11 (Reuters) - Assure Holdings Corp ( IONM ): * ASSURE HOLDINGS ENTERS INTO AGREEMENT TO SELL CERTAIN OF ITS ASSETS TO MPOWERHEALTH * ASSURE HOLDINGS CORP ( IONM ): TO SELL CERTAIN ASSETS OF ITS IONM BUSINESS TO MPOWERHEALTH FOR UP TO $4.5 MILLION Source text for Eikon: Further company coverage: ...